#breast cancer

The FDA has approved Pfizer and Arvinas’ vepdegestrant for a certain form of breast cancer, but the decision arrives with visible uncertainty about how broadly the drug will actually be used.

Roche says its investigational breast cancer pill giredestrant could still become a major product, with CEO Thomas Schinecker arguing it may one day outsell Herceptin despite an earlier first-line trial failure.

Drexel University researchers report a critical metabolic vulnerability in breast cancer that has spread to the brain, pointing toward a possible therapeutic target for one of oncology’s hardest problems.

A research team at Ben-Gurion University of the Negev says it has identified a protein that plays a central role in helping triple-negative breast cancer spread through the body.

New research finds that monthly telehealth nurse check-ins significantly improve treatment adherence among breast cancer patients on oral therapy, reducing the dropout rate by 17 percentage points.

A new mouse study finds that anthocyanin compounds in dark sweet cherries may slow the growth of triple-negative breast cancer, one of the most aggressive and hardest-to-treat forms of the disease.